Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
6,036 total articles
Coherent (COHR) has run hard after a multibillion Nvidia tie-up and product news, but the core fundamental driver is optical component demand and order flow. The setup favors a pullback entry to ride follow-on orders and supply tightness; valuation is rich and execution risk is real, so size positions conservatively and use a defined stop.
BitMine Immersion Technologies holds a large Ethereum treasury that currently exceeds its market cap. With signs of renewed institutional interest in digital-asset treasuries and the prospect of clearer legislation, BMNR looks structurally undervalued. This trade idea lays out an entry at $20.76, a stop at $16.00, and a target of $28.00 over a mid-…
Altria offers an attractive entry point for income-oriented traders who want upside from smoke-free adoption and near-term dividend capture. The company trades at a reasonable P/E and generates strong free cash flow versus dividend obligations, while technicals and short interest suggest limited downside momentum. This trade targets a measured long…
Amplify Energy (AMPY) is a small, asset-light E&P with recent asset sales, a clean credit line and modest leverage. In an Iran-driven spike in oil prices, AMPY's valuation, cash position and leverage profile could drive a fast, outsized move. This is a high-risk, high-reward swing trade sized for mid-term upside while protecting capital with a stri…
C4 Therapeutics (CCCC) has reignited interest after Phase 1 data and a program push for cemsidomide, an IKZF1/3 degrader for multiple myeloma. The stock is trading near its 52-week high as momentum accelerates; we outline a long trade that captures upside into clinical readouts while protecting capital if the story stalls.
Compass (COMP) just crossed an important inflection point: scale from the Anywhere merger plus positive free cash flow and sub-1x price-to-sales create an asymmetric risk/reward. I recommend a long entry at $9.06 with a $7.50 stop and a $13.00 target over the next 180 trading days, driven by $225M+ annual synergies, a $203M free cash flow base, and…
Salesforce recently sold off with the broader 'SaaSpocalypse' rout, but its fundamentals - record revenue cadence, $14.4B free cash flow, and a manageable balance sheet - argue for a tactical long. This idea outlines a mid-term (45 trading days) trade: entry at $198.79, target $250.00, stop $175.00. Reward-to-risk is attractive and several near-ter…
MasterCraft (MCFT) is trading below key moving averages and into oversold RSI territory after a pullback from its February highs. Fundamentals show profitable operations, solid free cash flow and a conservative balance sheet; the Marine Products acquisition and fresh product launches provide clear catalysts. This trade idea outlines an actionable l…
PayPal is trading like a broken growth story while quietly generating strong free cash flow, healthy ROE and an attractive EV/EBITDA. If management can steady execution after the CEO change and shore up Branded Checkout rollout, this name has asymmetric upside from current levels. This article lays out an actionable long trade with entry, stop and …
PG&E (PCG) is a structurally improved utility with roughly $40B market cap, improving profitability and a significant federal backstop. The stock trades near $18 and offers a shot at a re‑rating if operational execution and regulatory outcomes stay constructive. This trade favors a controlled long with a mid-term horizon to capture multiple catalys…
PayPal is a cash-generative payments platform trading at roughly $42-46 with a P/E near 8 and EV/EBITDA ~6. The market punished the name after a surprise CEO change and weak results, creating a low-multiple entry for patient, risk-aware buyers. This trade idea lays out an entry, stop and target for a 180-trading-day horizon and explains why I'll ke…
Rigel has turned a clear corner operationally: revenue upside from product sales and a deepening collaboration with Eli Lilly drove a 176% revenue jump in Q2 2025 and meaningful free cash flow. At a market cap of roughly $520M and EV/FCF near 7, the risk/reward for a long trade looks attractive. This idea lays out an entry at $28.00, stop at $24.00…
Helmerich & Payne is a cash-generative driller with an EV/EBITDA of ~6.8 and free cash flow of ~$180M. The stock trades near $34.37 and is fairly valued versus its fundamental cash returns; short-term upside is tied to Middle East dayrate strength and offshore/International exposure. We recommend a tactical long (mid-term, 45 trading days) with a c…
Tesla trades like a company priced for future breakthroughs. Its cash flow generation, low leverage, and scale mean a fresh, measurable move down the cost curve - a new Wright's Law inflection - would be a powerful catalyst for re-rating. This trade idea lays out an entry at current levels, a defined stop, and a mid-term target that captures a reac…
Rocket Lab (RKLB) remains priced like a single-success-or-fail bet on Neutron. I think the better trade is to focus on durable growth drivers already delivering revenue and margins: launch cadence, Space Systems, defense hypersonics, and the OSI acquisition. This trade idea outlines a tactical long entry to capture a mid-term rebound as execution o…
Park Aerospace supplies advanced composite and hot-melt materials used across aerospace and defense. With recent 20% sales growth and doubled EPS, no debt, and a multicast of defense spending tailwinds, PKE looks like a tactical long. Valuation is rich, and a $150M share-and-warrant deal introduces dilution risk — this trade pairs momentum with dis…
Douglas Dynamics has gone from recovery to record results in 2025 and is trading well above its 52-week low. Fundamentals and seasonality favor more upside; technicals and a compact float keep this a tradable long. Here’s a concrete entry, stop and target with rationale and risks.
Clarivate is cheap on multiple cash-based metrics. Recent Q4 beats, guidance for double-digit free cash flow growth, and talks to divest Life Sciences position it to materially cut leverage. If execution holds, the stock can re-rate from cyclical distressed multiples to a more normal software/analytics multiple. This trade targets a move to $6 on a…
Snowflake is down sharply in 2026 despite 30% revenue growth, improving AI positioning, and strong free cash flow. The pullback has created a tradable entry at $182.81 with asymmetric upside to $260 while limiting risk with a $150 stop. This is a long-term trade (180 trading days) sized to account for headline risk and execution uncertainty.
Riley Exploration (RILEY) is a small Permian-focused E&P that can deliver outsized returns if oil stays above $75/bbl. Public financial disclosure on the name is limited and liquidity can be thin, but the company's cost structure and drilling optionality give it attractive upside in a tightening crude market. This is a high-risk, high-reward trade …
Zeta Global (ZETA) has re-emerged as a growth story after a series of strong top-line prints and expanding free cash flow. The market has mostly reset expectations from its 2025 slump, yet valuation still implies meaningful future growth. This trade idea outlines a mid-term long with an entry near the current price, a stop below recent intraday low…
Copart (CPRT) checks the boxes for a tactical long: solid free cash flow ($1.41B), effectively no debt, and a share base that management can meaningfully pare without risking leverage. We recommend buying near $37.56 to play an expected repurchase cycle and earnings re-acceleration over the next 180 trading days.
The Trade Desk (TTD) has been pummeled from its highs but still runs a profitable, high-retention ad-tech engine. CEO Jeff Green's recent $148M buy is a meaningful signal. This trade idea lays out a mid-term long with a clearly defined entry, stop and target, anchored to fundamentals (record 2025 revenue, strong FCF) and near-term catalysts (OpenAI…
Navan's share price sits near the low of its first year public, trading at roughly $10 with a $2.46B market cap. Technicals show short-term stabilization and bullish MACD momentum, while headlines about rising sales & marketing spend and pending securities suits keep sentiment weak. This trade idea outlines a mid-term (45 trading days) long with an…
HIMS gapped higher after settling with Novo Nordisk and striking a distribution deal for Wegovy/Ozempic; the move removes a headline risk and creates a tactical mid-term buying opportunity. Valuation is reasonable relative to growth expectations but volatility, execution risk on international expansion, and GLP-1 market dynamics argue for a discipl…
